share_log

Virpax Pharmaceuticals | 8-K: Current report

SEC announcement ·  Apr 30 19:40
Summary by Futu AI
Virpax Pharmaceuticals, Inc., a Delaware-based company, announced on April 30, 2024, the results of a Maximum Tolerated Dose (MTD) study for its drug Probudur, conducted on Sprague-Dawley rats. Probudur is a long-acting liposomal bupivacaine formulation designed for post-operative pain management, aiming to reduce or eliminate the need for opioids. The study aimed to determine the MTD of Probudur, both alone and in combination with free bupivacaine, when administered as a single subcutaneous injection. The results indicated that all doses of Probudur were well-tolerated, with no significant effects on body weight, clinical chemistry, hematology, or coagulation. Histopathology showed minimal to moderate changes at the injection site, with slightly more pronounced effects at higher doses. The company plans to file an Investigational New Drug Application (IND) for Probudur by the end of the year. Virpax is also developing other non-addictive pain management products and has cooperative research and development agreements with the NIH and DOD.
Virpax Pharmaceuticals, Inc., a Delaware-based company, announced on April 30, 2024, the results of a Maximum Tolerated Dose (MTD) study for its drug Probudur, conducted on Sprague-Dawley rats. Probudur is a long-acting liposomal bupivacaine formulation designed for post-operative pain management, aiming to reduce or eliminate the need for opioids. The study aimed to determine the MTD of Probudur, both alone and in combination with free bupivacaine, when administered as a single subcutaneous injection. The results indicated that all doses of Probudur were well-tolerated, with no significant effects on body weight, clinical chemistry, hematology, or coagulation. Histopathology showed minimal to moderate changes at the injection site, with slightly more pronounced effects at higher doses. The company plans to file an Investigational New Drug Application (IND) for Probudur by the end of the year. Virpax is also developing other non-addictive pain management products and has cooperative research and development agreements with the NIH and DOD.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.